RECURRENT INTRAHEPATIC CHOLANGIOCARCINOMA
Clinical trials for RECURRENT INTRAHEPATIC CHOLANGIOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT INTRAHEPATIC CHOLANGIOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT INTRAHEPATIC CHOLANGIOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo attack on biliary cancers: targeted drug plus chemo shows promise
Disease control OngoingThis study tests whether adding the targeted drug binimetinib to standard chemotherapy (mFOLFOX6) can shrink tumors or extend survival in people with advanced biliary tract cancers that have certain genetic changes (MAPK pathway alterations). About 66 participants whose cancer wo…
Matched conditions: RECURRENT INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase trial is testing a combination of two drugs—guadecitabine and durvalumab—in 55 people with advanced liver, pancreatic, bile duct, or gallbladder cancers that have spread. Guadecitabine aims to stop cancer cell growth, while durvalumab helps the immune system atta…
Matched conditions: RECURRENT INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC